Literature DB >> 19184655

Effects of nicotine in experimental animals and humans: an update on addictive properties.

Bernard Le Foll1, Steven R Goldberg.   

Abstract

Tobacco use through cigarette smoking is the leading preventable cause of death in the developed world. Nicotine, a psychoactive component of tobacco, appears to play a major role in tobacco dependence, but the reinforcing effects of nicotine have often been difficult to demonstrate directly in controlled studies with laboratory animals or human subjects. Here we update our earlier review published in Psychopharmacology (Berl) in 2006 on findings obtained with various procedures developed to study dependence-related behavioral effects of nicotine in experimental animals and humans. Results obtained with drug self-administration, conditioned place preference, subjective reports of nicotine effects and nicotine discrimination indicate that nicotine can function as an effective reinforcer of drug-seeking and drug-taking behavior both in experimental animals and humans under appropriate conditions. Interruption of chronic nicotine exposure produces ratings of drug withdrawal and withdrawal symptoms that may contribute to relapse. Difficulties encountered in demonstrating reinforcing effects of nicotine under some conditions, relative to other drugs of abuse, may be due to weaker primary reinforcing effects of nicotine, to aversive effects produced by nicotine, or to a more critical contribution of environmental stimuli to the maintenance of drug-seeking and drug-taking behavior with nicotine than with other drugs of abuse. Several recent reports suggest that other chemical substances inhaled along with nicotine in tobacco smoke may play a role in sustaining smoking behavior. However, conflicting results have been obtained with mice and rats and these findings have not yet been validated in nonhuman primates or human subjects. Taken together, these findings suggest that nicotine acts as a typical drug of abuse in experimental animals and humans in appropriate situations.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19184655      PMCID: PMC2687081          DOI: 10.1007/978-3-540-69248-5_12

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN: 0171-2004


  232 in total

Review 1.  Incentive-sensitization and addiction.

Authors:  T E Robinson; K C Berridge
Journal:  Addiction       Date:  2001-01       Impact factor: 6.526

2.  Depressive characteristics of FSL rats: involvement of central nicotinic receptors.

Authors:  Y Tizabi; A H Rezvani1; L T Russell; K Y Tyler; D H Overstreet
Journal:  Pharmacol Biochem Behav       Date:  2000-05       Impact factor: 3.533

3.  Extended access to nicotine self-administration leads to dependence: Circadian measures, withdrawal measures, and extinction behavior in rats.

Authors:  Laura E O'Dell; Scott A Chen; Ron T Smith; Sheila E Specio; Robert L Balster; Neil E Paterson; Athina Markou; Eric P Zorrilla; George F Koob
Journal:  J Pharmacol Exp Ther       Date:  2006-10-18       Impact factor: 4.030

4.  Control of behavior by intravenous nicotine injections in laboratory animals.

Authors:  S R Goldberg; R D Spealman; M E Risner; J E Henningfield
Journal:  Pharmacol Biochem Behav       Date:  1983-12       Impact factor: 3.533

5.  Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid.

Authors:  H Rollema; L K Chambers; J W Coe; J Glowa; R S Hurst; L A Lebel; Y Lu; R S Mansbach; R J Mather; C C Rovetti; S B Sands; E Schaeffer; D W Schulz; F D Tingley; K E Williams
Journal:  Neuropharmacology       Date:  2006-12-08       Impact factor: 5.250

6.  Acquisition of nicotine self-administration in rats: the effects of dose, feeding schedule, and drug contingency.

Authors:  E C Donny; A R Caggiula; M M Mielke; K S Jacobs; C Rose; A F Sved
Journal:  Psychopharmacology (Berl)       Date:  1998-03       Impact factor: 4.530

7.  Metabotropic glutamate 2/3 receptors in the ventral tegmental area and the nucleus accumbens shell are involved in behaviors relating to nicotine dependence.

Authors:  Matthias E Liechti; Loic Lhuillier; Klemens Kaupmann; Athina Markou
Journal:  J Neurosci       Date:  2007-08-22       Impact factor: 6.167

Review 8.  Clinical efficacy of bupropion in the management of smoking cessation.

Authors:  Douglas Jorenby
Journal:  Drugs       Date:  2002       Impact factor: 9.546

9.  Evidence for addiction-like behavior in the rat.

Authors:  Véronique Deroche-Gamonet; David Belin; Pier Vincenzo Piazza
Journal:  Science       Date:  2004-08-13       Impact factor: 47.728

10.  Nicotine-induced conditioned place preference in adolescent and adult rats.

Authors:  Bonnie J Vastola; Lewis A Douglas; Elena I Varlinskaya; Linda P Spear
Journal:  Physiol Behav       Date:  2002-09
View more
  63 in total

1.  Repeated nicotine administration robustly increases bPiDDB inhibitory potency at alpha6beta2-containing nicotinic receptors mediating nicotine-evoked dopamine release.

Authors:  Andrew M Smith; Marharyta Pivavarchyk; Thomas E Wooters; Zhenfa Zhang; Guangrong Zheng; J Michael McIntosh; Peter A Crooks; Michael T Bardo; Linda P Dwoskin
Journal:  Biochem Pharmacol       Date:  2010-03-25       Impact factor: 5.858

2.  Nicotine reinforcement in never-smokers.

Authors:  Angela N Duke; Matthew W Johnson; Chad J Reissig; Roland R Griffiths
Journal:  Psychopharmacology (Berl)       Date:  2015-09-08       Impact factor: 4.530

3.  The sensitizing effect of acute nicotine on amphetamine-stimulated behavior and dopamine efflux requires activation of β2 subunit-containing nicotinic acetylcholine receptors and glutamate N-methyl-D-aspartate receptors.

Authors:  Myung N Kim; Emily M Jutkiewicz; Minjia Zhang; Margaret E Gnegy
Journal:  Neuropharmacology       Date:  2010-10-28       Impact factor: 5.250

4.  Noradrenergic alpha1 receptors as a novel target for the treatment of nicotine addiction.

Authors:  Benoit Forget; Carrie Wertheim; Paola Mascia; Abhiram Pushparaj; Steven R Goldberg; Bernard Le Foll
Journal:  Neuropsychopharmacology       Date:  2010-03-31       Impact factor: 7.853

5.  The novel nicotinic receptor antagonist, N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide (bPiDDB), inhibits nicotine-evoked [(3)H]norepinephrine overflow from rat hippocampal slices.

Authors:  Andrew M Smith; Gurpreet K Dhawan; Zhenfa Zhang; Kiran B Siripurapu; Peter A Crooks; Linda P Dwoskin
Journal:  Biochem Pharmacol       Date:  2009-07-23       Impact factor: 5.858

6.  Effects of orally-bioavailable short-acting kappa opioid receptor-selective antagonist LY2456302 on nicotine withdrawal in mice.

Authors:  Kia J Jackson; Asti Jackson; F Ivy Carroll; M Imad Damaj
Journal:  Neuropharmacology       Date:  2015-06-01       Impact factor: 5.250

7.  Effects of nicotine on olfactogustatory incentives: preference, palatability, and operant choice tests.

Authors:  Matthew I Palmatier; Jaden E Lantz; Laura C O'Brien; Sarah P Metz
Journal:  Nicotine Tob Res       Date:  2013-02-21       Impact factor: 4.244

8.  Pharmacological modulation of the α7 nicotinic acetylcholine receptor in a mouse model of mecamylamine-precipitated nicotine withdrawal.

Authors:  Asti Jackson; Roger L Papke; M Imad Damaj
Journal:  Psychopharmacology (Berl)       Date:  2018-03-16       Impact factor: 4.530

9.  Discriminative stimulus and hypothermic effects of some derivatives of the nAChR agonist epibatidine in mice.

Authors:  Jesse S Rodriguez; Colin S Cunningham; Fernando B Moura; Pauline Ondachi; F Ivy Carroll; Lance R McMahon
Journal:  Psychopharmacology (Berl)       Date:  2014-05-07       Impact factor: 4.530

Review 10.  Hormones, nicotine, and cocaine: clinical studies.

Authors:  Nancy K Mello
Journal:  Horm Behav       Date:  2009-10-14       Impact factor: 3.587

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.